Omalizumab is an effective add-on therapy in moderate-to-severe allergic asthma


    loading  Checking for direct PDF access through Ovid

Abstract

Omalizumab, a humanised monoclonal antibody, selectively binds to circulating IgE, thereby preventing cellular activation and subsequent asthma symptoms. When used as add-on therapy with inhaled corticosteroids (ICSs), omalizumab reduces the number of asthma exacerbations, decreases rescue medication use, improves asthma symptom and asthma-related quality-of-life scores, is generally well tolerated and often allows for ICS dosage reduction.

    loading  Loading Related Articles